All In Biotech

Drug Trial Radar · NCT03758664

Clinical Study of ICP-192 in Solid Tumors Patients

A Phase I/IIa, Multicenter, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics of ICP-192 in Patients With Advanced Solid Malignancies

Last checked: Nov 19, 2026Latest source record: Jul 6, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

56

Planned (sponsor's estimate)

Start

Dec 19, 2018

Primary completion

Dec 31, 2024

Study completion Dec 31, 2024

Sponsor

Sponsor type
Industry
First posted
Nov 29, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Open-label, non-randomized, Phase I/IIa, dose-escalating, dose-extension, first-in-man study.

Conditions

  • Solid Tumor

Interventions

  • ICP-192Drug

    Drug: ICP-192 Dose levels will be escalated following accelerated titration and modified "3+3" dose escalation scheme,

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events(Phase 1 dose escalation)Time frame: From the time a signed and dated ICF until 28 days after last dose of study drug
  2. Objective Response Rate(ORR)(Phase 2a dose expansion)Time frame: At the end of Cycle 4(each cycle is 21 days)

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • ZhuJiang Hospital of Southern Medical University

    Guangzhou, Guangdong, China · Not yet recruiting

  • Henan cancer hospital & Affiliated Tumor Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Not yet recruiting

  • Hunan cancer hospital & the affiliated cancer hospital of xiangya school of medicine ,central south university

    Changsha, Hunan, China · Not yet recruiting

  • The Second Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China · Not yet recruiting

  • The First Bethune Hospital of Jilin University

    Changchun, Jilin, China · Not yet recruiting

  • Shanghai East Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • Cancer hospital of the university of Chinese academy of sciences

    Hangzhou, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.